Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 22 | 730 | 37 | 1,424 |
| Operating expenses: | ||||
| Research and development | 67,542 | 54,196 | 140,543 | 106,810 |
| General and administrative | 13,103 | 10,391 | 24,552 | 21,211 |
| Total operating expenses | 80,645 | 64,587 | 165,095 | 128,021 |
| Operating loss | (80,623) | (63,857) | (165,058) | (126,597) |
| Investment and other income, net | 7,120 | 7,257 | 12,870 | 16,201 |
| Net loss | $(73,503) | $(56,600) | $(152,188) | $(110,396) |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's G&A?
- Celldex Therapeutics (CLDX) reported G&A of $13.1M in Q2 2026.
- How has Celldex Therapeutics's G&A changed year-over-year?
- Celldex Therapeutics's G&A increased by 26.1% year-over-year, from $10.39M to $13.1M.
- What is the long-term trend for Celldex Therapeutics's G&A?
- Over 4 years (2021 to 2025), Celldex Therapeutics's G&A has grown at a 20.9% compound annual growth rate (CAGR), from $20.49M to $43.84M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Celldex Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude